USA: Johnson & Johnson releases full-year results

Johnson & Johnson has closed 2014 recording total sales of $74.3 billion, an increase of 4.2% versus 2013.

In the Worldwide Consumer division, however, sales of $14.5 billion for the full-year 2014 represented a decrease of 1.4% compared to 2013, consisting of an operational increase of 1.0% and a negative impact from currency of 2.4%. Domestic sales decreased 1.3% while international sales decreased 1.4%, reflecting an operational increase of 2.3% and a negative currency impact of 3.7%.

Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 2.8%, domestic sales increased 3.1% and international sales increased 2.6%. Positive contributors to operational results were the Aveeno and Neutrogena skin care brands and Listerine oral care products, the company said.

Commenting on the results, Chairman and Chief Executive Officer Alex Gorsky said: "2014 was a strong year for Johnson & Johnson, as we delivered solid financial results while continuing to make investments to accelerate growth for the long term. We have built significant momentum in our Pharmaceutical business, are realizing the benefits of innovation, scale and breadth in our Medical Devices business and are continuing our market leadership with iconic brands in our Consumer business".

Source: Johnson & Johnson